Department of Neurology, Jinling Hospital, Medical School of Southeast University, Nanjing, Jiangsu, China.
Department of Neurology, Jinling Hospital, Medical School of Nanjing University, Xuanwu District, No. 305 Zhongshan East Road, Nanjing, 210002, Jiangsu, China.
J Thromb Thrombolysis. 2021 Jul;52(1):291-300. doi: 10.1007/s11239-020-02307-0. Epub 2020 Oct 20.
Direct mechanical thrombectomy (DMT) was confirmed non-inferior to bridge mechanical thrombectomy (BMT, MT preceded by intravenous alteplase within 4.5 h after symptom onset) for acute ischemic stroke with large vessel occlusions (AIS-LVO) in mothership patients. However, the noninferiority of DMT in the general population (including drip and ship mode) is controversial, and the impact of thrombolysis on retrieval attempts remains uncertain. This was a post-hoc analysis of a multi-center, prospective enrolled study. Patients were divided into the BMT group and the DMT group. Baseline characteristics and clinical outcomes were compared by using univariate analysis, multivariable analysis, and propensity score matching analysis, respectively. Of all 245 patients enrolled in this study, 79 (32.2%) patients underwent BMT. In the multivariable analysis, the ratio of excellent prognosis (defined as modified Rankin Scale [mRS] score 0-1 at 90 days) was significantly higher in the BMT group compared with the DMT group (odds ratio, 2.731; 95% confidence interval, 1.238-6.023; P = 0.013). The ratio of good prognosis (mRS score 0-2 at 90 days), successful recanalization rate [modified Thrombolysis In Cerebral Ischemia (mTICI) score 2b-3] and mortality rate were similar between the two groups. The excellent prognosis rate was significantly higher in the BMT group after propensity score matching (P = 0.023). BMT was associated with a higher ratio of excellent prognosis (mRS 0-1) and a similar successful recanalization rate without increasing peri-operation complications compared with DMT in AIS-LVO patients. It is prudent to continue BMT until further data is available.
直接机械取栓(DMT)已被证实不劣于桥接机械取栓(BMT,即在症状发作后 4.5 小时内静脉注射阿替普酶,随后进行机械取栓),用于治疗大动脉闭塞性急性缺血性脑卒中(AIS-LVO)。然而,DMT 在普通人群(包括滴注和桥接模式)中的非劣效性仍存在争议,溶栓对取栓尝试的影响仍不确定。这是一项多中心前瞻性研究的事后分析。患者被分为 BMT 组和 DMT 组。分别采用单因素分析、多因素分析和倾向评分匹配分析比较两组的基线特征和临床结局。在这项研究中,共纳入 245 例患者,其中 79 例(32.2%)接受了 BMT。多因素分析显示,BMT 组的预后良好率(定义为 90 天时改良 Rankin 量表评分 0-1)明显高于 DMT 组(比值比 2.731,95%置信区间 1.238-6.023,P=0.013)。两组的良好预后率(90 天时改良 Rankin 量表评分 0-2)、再通率(改良脑梗死溶栓分级[mTICI]评分 2b-3)和死亡率相似。经倾向评分匹配后,BMT 组的预后良好率显著高于 DMT 组(P=0.023)。在 AIS-LVO 患者中,与 DMT 相比,BMT 可获得更高的预后良好率(mRS 0-1)和相似的再通率,且不增加围手术期并发症,因此可以继续使用 BMT,直至有更多数据支持。